Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Century Therapeutics Inc
(NQ:
IPSC
)
1.210
-0.030 (-2.41%)
Streaming Delayed Price
Updated: 9:35 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Century Therapeutics Inc
< Previous
1
2
3
4
Next >
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
January 06, 2023
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.
Via
InvestorPlace
8 Analysts Have This to Say About Century Therapeutics
January 06, 2023
Via
Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
January 06, 2023
Via
Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
January 05, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
December 27, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
December 20, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
November 11, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
November 02, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
Century Therapeutics to Present at the SITC 37th Annual Meeting
October 05, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
October 03, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 25, 2022
Via
Benzinga
FDA Announced Clearance To Century Therapeutics' Allogeneic Cell Therapy Candidate Study
August 25, 2022
Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or...
Via
Benzinga
U.S. Stock Futures Higher Following Friday's Rally
June 27, 2022
Pre-open movers
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
February 08, 2022
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 01, 2022
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...
Via
Benzinga
45 Stocks Moving In Monday's Mid-Day Session
January 10, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...
Via
Benzinga
60 Biggest Movers From Yesterday
January 11, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 10, 2022
Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The company's market cap stands at $674.6 million. Apria (...
Via
Benzinga
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
January 10, 2022
Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to...
Via
Benzinga
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
January 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
35 Biggest Movers From Friday
October 11, 2021
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for...
Via
Benzinga
Exposures
Product Safety
51 Biggest Movers From Yesterday
December 28, 2021
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...
Via
Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.